Application of Circulating Tumor Cells in Peripheral Blood in Judging the Prognosis of Patients with Renal Cancer and Related Indexes of Blood Coagulation

Objective: To investigate the value of the number of circulating tumor cells (CTC) in peripheral blood in the prognosis and coagulation-related indicators of patients with renal cancer. Methods: 65 patients with renal cell carcinoma (RCC) confirmed pathologically were divided into CTC positive group and CTC negative group according to the CTC count (5 pcs/3.5 ml). Compare the age, gender, tumor location, TNM (clinical stage), pathological grade, tissue type, lymph node metastasis, distant metastasis, prognosis and prothrombin time (PT), fibrinogen (FIB), partial coagulation of the two groups of patients The correlation between the results of zymogen time (APTT) and D-dimer (DD) and the number of CTC. Results: There were significant differences in TNM, lymph node metastasis, and distant metastasis between the two groups (P < 0.05). The number of CTC in patients was correlated with FIB and D-D levels (P < 0.05). Conclusion: The number of CTC in patients with renal cell carcinoma is correlated with some clinical phenotypes (TNM, lymph node metastasis, distant metastasis) and some coagulation indexes (FIB, D-D), and can jointly predict the prognosis of renal cancer.

Clinical Value of Peripheral Blood Circulating Tumor Cells and Cell-Free DNA Combined Detection in Triple-Negative Breast Cancer

Objective:To determine the clinical value of combined detection of circulating tumor cells(CTCs)and cell-free DNA(cfDNA)in peripheral blood of patients with triple-negative breast cancer.Method:41 patients with breast cancer admitted to the First Central Hospital of Baoding from January 2020 to December 2021 were selected and recruited into the experimental group,42 patients with benign breast cancer admitted during the same period were recruited into the conditional control group,and 41 healthy patients admitted during the same period were recruited into the blank control group.The positive rate of peripheral blood CTCs,the level of cfDNA,and the diagnostic efficacy of peripheral blood CTCs,cfDNA alone and the combination thereof for breast cancer were analyzed.Result:The positive rates of peripheral blood CTCs in the experimental group,the conditional control group,and the blank control group were 43.90%,11.90%,and 9.74%,respectively,and there was significant difference among the groups.The levels of cfDNA in peripheral blood of the experimental group,the conditional control group,and the blank control group were 0.26±0.08 bp,0.17±0.03 bp,and 0.15±0.04 bp,respectively,which were statistically significant.The detection levels of 100 bp hTERT/ng mT1 and 241 bp hTERT/ng-mT1 in the experimental group were significantly higher than those in the conditional control group and the blank control group.The accuracy of peripheral blood CTCs detection in the three groups was 66.21%,the accuracy of cfDA241 bp/100 hp hTERT detection was 80.41%,and the accuracy of combined detection of peripheral blood CTCs and cfDNA was 94.03%.Conclusion:The clinical application of peripheral blood CTCs combined with cfDNA level detection can increase detection accuracy,provide data support for clinicians,and improve the clinical diagnostic effect of triple-negative breast cancer.

A Correlation Analysis of Postoperative Hypercoagulability and Peripheral Circulating Tumor Cells in Patients with Lung Cancer

Objective:To explore the correlation between peripheral circulating tumor cells and hypercoagulability in patients with lung cancer after surgery.Methods:From January 2017 to December 2021,89 patients with lung cancer who were treated in the Affiliated Hospital of Hebei University were selected as the research subjects,and a retrospective analysis was conducted to analyze and observe the D-dimer(DD),fibrinogen(FIB),and platelet(PLT)levels in peripheral blood,as well as detect peripheral CTC.Results:There were statistical differences in TMN staging,tumor metastasis,and lymph node metastasis in the clinical data,but there were no statistical differences in gender,smoking history,and pathological classification.After retrospective analysis and comparison of the patients,the DD(mg/ml),FIB(g/L),and PLT(×10^(9)/L)levels of the CTC positive group were 3.41±0.58,3.98±0.87,and 367.26±34.98,respectively;the CTC negative group’s DD(mg/ml),FIB(g/L),and PLT(×10^(9)/L)levels were 0.89±0.49,1.06±0.45,and 234.69±35.69,respectively,and the differences were statistically significant.The factors affecting the prognosis of patients included TMN staging and CTC;the number of CTC positives in the death group was significantly higher than that in the survival group,and there was a statistical difference between the groups.Gender,age,smoking history,pathological type,and surgical resection had no effect on the prognosis of patients.Among the enrolled patients,the survival rate was 71.91%.Conclusion:CTC-positive patients have a higher probability of hypercoagulability after surgery and are prone to tumor metastasis;thus,CTC can be used as a judgment index for the prognosis of patients.

Cultured circulating tumor cells and their derived xenografts for personalized oncology

Recent cancer research has demonstrated the existence of circulating tumor cells(CTCs)in cancer patient’s blood.Once identified,CTC biomarkers will be invaluable tools for clinical diagnosis,prognosis and treatment.In this review,we propose ex vivo culture as a rational strategy for large scale amplification of the limited numbers of CTCs from a patient sample,to derive enough CTCs for accurate and reproducible characterization of the biophysical,biochemical,gene expressional and behavioral properties of the harvested cells.Because of tumor cell heterogeneity,it is important to amplify all the CTCs in a blood sample for a comprehensive understanding of their role in cancer metastasis.By analyzing critical steps and technical issues in ex vivo CTC culture,we developed a cost-effective and reproducible protocol directly culturing whole peripheral blood mononuclear cells,relying on an assumed survival advantage in CTCs and CTC-like cells over the normal cells to amplify this specified cluster of cancer cells.

Relationship between Single Nucleotide Polymorphism in TNF-α Gene Promoter Region and Inhibitory Effects of Triptolide on TNF-α Production in Peripheral Blood Mononuclear Cells of Healthy Humans

The relationship between tumour necrosis lactose （TNF-α） gene polymorphism and inhibitory effects of triptolide on TNF-α production from peripheral blood mononuclear cells （PBMC） of healthy humans was investigated. Genomic DNA from 41 healthy people was typed for TNF-α- 308 polymorphism by allele-specific polymorphism chain reaction （AS-PCR）. The TNF-α concentration in the supernatant was measured by ELISA. The results showed that the production of TNF-α from TNF-α -308 non-G/G genotype PBMC was higher than that from TNF-α-308 G/G genotype PBMC after stimulated by LPS. Triptolide could lower the production of TNF-α from G/ G genotype PBMC, but had no effect on the level of TNF-α from non-G/G genotype PBMC. It was concluded that TNF-α gene polymorphism was related to the TNF-α production from triptolide-inhibited PBMC culture in healthy humans.

Lactobacilli,bifi dobacteria and E.coli nissle induce pro-and anti-inflammatory cytokines in peripheral blood mononuclear cells

AIM: To investigate whether the stimulation of peripher- al blood mononuclear cells (PBMNC) with the cell debris and cell extraction of different probiotic strains is similar or species specifi c. METHODS: Three strains of bifi dobacteria, 4 strains of lactobacilli, and E. coli nissle were sonicated and centri- fuged in order to divide them into cell extract and cell debris. PBMNC were separated by density gradient and incubated for 36 h with either the cell debris or the cell extract of single strains of probiotic bacteria in doses from 102 to 108 CFU/mL. Cell supernatants were taken and interleukin (IL)-10, IL-1β, and tumor necosis factor (TNF)-α were determined by ELISA. RESULTS: Depending on the species super-family, the strains had different stimulation patterns. Except for both L. casei strains, the cell extract of bifidobacteriaand lactobacilli had less stimulating capacity than cell debris, whereas the cell extract of E. coli nissle had simi- lar stimulating properties to that of the cell debris of the strain and significantly more stimulating capacity than that of bifi dobacteria and lactobacilli. The cell debris of bifi dobacteria stimulated more cytokine release than the cell debris of lactobacilli. The cell debris of lactobacilli did not have a stimulating capacity when lower concentra- tions were used. Neither cell extraction nor cell debris had an inhibitory effect on the production of the tested cytokines by stimulated PBMNC. CONCLUSION: The incubation of probiotic strains, which have been used in clinical trials for inflammatory diseases, with immunocompetent cells leads to different species specifi c reactions. High IL-10 response to cell de- bris of bifi dobacteria and E. coli nissle can be found. This corresponds to positive effects of bifi dobacteria and E. coli nissle in clinical trials for inflammatory bowel disease compared to negative outcomes obtained with lactoba- cilli.

Circulating cytokeratin-positive cells and tumor budding in colorectal cancer

AIM To investigate whether circulating cytokeratin-positive(CK^+) cells in the mesenteric blood of resected colorectal specimens are prognostic and correlate with tumor budding.METHODS Fifty-six colorectal specimens were collected between 9/2007 and 7/2008.Blood from the mesenteric vein was drawn immediately after receiving the fresh and unfixed specimens in the pathology department.After separation of the mononuclear cells by Ficoll-Hypaquedensity-gradient centrifugation,cytological smears were immunocytochemically stained for CK18.Tumor budding was evaluated on slides stained for pan-cytokeratin.The identification of ≥ 30 buds/1.3 mm2 was defined as high grade budding.RESULTS CK^+ cells and clusters were identified in 29(48%) and 14(25%) of the samples,respectively.Two cells were identified in one of three non-malignant cases.Clusters were found exclusively in malignant cases.The occurrence of CK^+ cells or clusters was not associated with any of the evaluated clinicopathological factors,including surgical technique and tumor budding.Moreover,the occurrence of CK^+ cells or clusters had no influence on the cancerspecific survival [75 mo(CI:61;88) vs 83 mo(CI:72;95) and 80 mo(CI:63;98) vs 79 mo(CI:69;89),respectively].CONCLUSION CK^+ cells and showed neither prognostic significance nor an association with tumor budding.It is very likely that CK18-staining is not specific enough to identify the relevant cells.

On-chip circulating tumor cells isolation based on membrane filtration and immuno-magnetic bead clump capture

Isolating rare circulating tumor cells(CTCs)from blood is critical for the downstream analysis that is important in cancer-related research,diagnosis,and medicine,and efforts are ongoing to increase the efficiency and purity of CTC isolation in microfluidics.Reported in this paper is a two-stage integrated microfluidic chip for coarse-to-fine CTC isolation from whole blood.First,blood cells are removed by filtration using a micropore-array membrane,then CTCs and other cells that are trapped in the micropores are peeled off the membrane by a novel release method based on air–liquid interfacial tension,which significantly increases the recovery rate of CTCs.The second stage is CTC capture based on an on-chip dense immuno-magnetic-bead clump,which offers high capture efficiency and purity.Both the micropore filtration and immuno-magnetic-bead capture are validated and optimized experimentally.Overall,the integrated microfluidic chip can realize a recovery rate of 85.5%and a purity of 37.8%for rare cancer cells spiked in whole blood.

Effect of Shenqi Fuzheng Injection combined with chemotherapy on peripheral blood cell level, tumor markers and immune function in patients with gastric cancer

Objective:To investigate the effects of Shenqi Fuzheng Injection combined with chemotherapy on peripheral blood cell level, tumor markers and immune function in patients with gastric cancer.Methods: Eighty patients with gastric cancer admitted to our hospital from May 2016 to October 2017 were selected as the research object and randomly divided into observation group and control group, 40 cases in each group. Control group was treated by DCF chemotherapy, while the observation group by Shenqi Fuzheng Injection based on the DCF chemotherapy. The levels of peripheral blood cells, tumor markers and immune function indexes in both groups were detected and compared before and after treatment.Results: There were no significant differences in serum RBC, WBC, PLT, Hb, NSE, CYFRA21-1, CA199, CEA, CD3+, CD4+, CD8+ and CD4+/CD8+ levels before treatment in both groups. Compared with the pretreatment group, the levels of RBC, WBC, PLT and Hb in both groups decreased to some extent after treatment, and the levels in the observation group were significantly higher than those in the control group;Compared with the same group before treatment, the levels of NSE, CYFRA21-1, CA199 and CEA in the two groups were significantly decreased, and the observation group was significantly lower than the control group;CD3+, CD4+, CD4+/CD8+ levels in control group and observation group increased to some extent after treatment, and the levels in observation group were significantly higher than those in control group. The levels of CD8+ in both groups after treatment were significantly lower than those before treatment, and the observation group was significantly lower than the control group after treatment. The above data for statistical analysis had significant differences.Conclusions: Shenqi Fuzheng injection combined with chemotherapy helps to clear and kill cancer cells, enhance immunity and reduce hematological toxicity after chemotherapy, which can be used as an adjuvant chemotherapy for gastric cancer.

Influence of granulocyte-macrophage colonystimulating factor and tumor necrosis factor on anti-hepatoma activities of human dendritic cells

INTRODUCTIONDendritic cells (DCs) play a key regulatory role inantitumor immunity,especially in its immuneaccessory role via MHC-Ⅰ molecules.We haverecently reported that DCs were able to enhance thekilling activity of Lymphokine and PHA activatedkiller (LPAK) cells in vitro.In the presentstudy,we evaluated the effects of GM-CSF andTNF upon antitumor activities of freshly

Squamous cell carcinoma of the oral cavity and circulating tumour cells

Due to a lack of substantial improvement in the outcome of patients suffering from oral squamous cell carcinoma(OSCC) during the past decades, current staging methods need to be revised. This disease is associated with poor survival rates despite considerable advances in diagnosis and treatment. The early detection of metastases is an important indicator of survival, prognosis and relapse. Therefore, a better understanding of the mechanisms underlying metastasis is crucial. Exploring alternative measures apart from common procedures is needed to identify new prognostic markers. Similar to previous findings predominantly for other solid tumours, recently published studies demonstrate that circulating tumour cells(CTCs) and disseminated tumour cells(DTCs) might serve as prognostic markers and could supplement routine staging in OSCC. Thus, the detection of CTCs/DTCs is a promising tool todetermine the individual need for therapeutic intervention. Encouraging results and new approaches point to the future use of targeted therapies for OSCC, an exceedingly heterogeneous subgroup of head and neck cancer. This review focuses on summarising technologies currently used to detect CTCs/DTCs. The translational relevance for OSCC is highlighted. The inherent challenges in detecting CTCs/DTCs will be emphasised.

Establishment of a humanized mouse model using steady-state peripheral blood-derived hematopoietic stem and progenitor cells facilitates screening of cancer-targeted T-cell repertoires

Background:Cancer-targeted T-cell receptor T(TCR-T)cells hold promise in treating cancers such as hematological malignancies and breast cancers.However,approaches to obtain cancer-reactive TCR-T cells have been unsuccessful.Methods:Here,we developed a novel strategy to screen for cancer-targeted TCR-T cells using a special humanized mouse model with person-specific immune fingerprints.Rare steady-state circulating hematopoietic stem and progenitor cells were expanded via three-dimensional culture of steady-state peripheral blood mononuclear cells,and then the expanded cells were applied to establish humanized mice.The human immune system was evaluated according to the kinetics of dendritic cells,monocytes,T-cell subsets,and cytokines.To fully stimulate the immune response and to obtain B-cell precursor NAML-6-and triple-negative breast cancer MDA-MB-231-targeted TCR-T cells,we used the inactivated cells above to treat humanized mice twice a day every 7 days.Then,human T cells were processed for TCRβ-chain(TRB)sequencing analysis.After the repertoires had been constructed,features such as the fraction,diversity,and immune signature were investigated.Results:The results demonstrated an increase in diversity and clonality of T cells after treatment.The preferential usage and features of TRBV,TRBJ,and the V–J combination were also changed.The stress also induced highly clonal Science and Technology,Grant/Award Number:2021C03010;Zhejiang Provincial Natural Science Foundation of China,Grant/Award Numbers:LTGY24H080003,LY21H080004 expansion.Tumor burden and survival analysis demonstrated that stress induction could significantly inhibit the growth of subsequently transfused live tumor cells and prolong the survival of the humanized mice.Conclusions:We constructed a personalized humanized mouse model to screen cancer-targeted TCR-T pools.Our platform provides an effective source of cancer-targeted TCR-T cells and allows for the design of patient-specific engineered T cells.It therefore has the potential to greatly benefit cancer treatment.

Antibody-engineered red blood cell interface for high-performance capture and release of circulating tumor cells

Circulating tumor cells(CTCs),as important liquid biopsy target,can provide valuable information for cancer progress monitoring and individualized treatment.However,current isolation platforms incapable of balancing capture efficiency,specificity,cell viability,and gentle release have restricted the clinical applications of CTCs.Herein,inspired by the structure and functional merits of natural membrane interfaces,we established an antibody-engineered red blood cell(RBC-Ab)affinity interface on microfluidic chip for high-performance isolation and release of CTCs.The lateral fluidity,pliability,and anti-adhesion property of the RBC microfluidic interface enabled efficient CTCs capture(96.5%),high CTCs viability(96.1%),and high CTCs purity(average 4.2-log depletion of leukocytes).More importantly,selective lysis of RBCs by simply changing the salt concentration was utilized to destroy the affinity interface for efficient and gentle release of CTCs without nucleic acid contamination.Using this chip,CTCs were successfully detected in colon cancer samples with 90%sensitivity and 100%specificity(20 patients and 10 healthy individuals).After the release process,KRAS gene mutations of CTCs were identified from all the 5 cancer samples,which was consistent with the results of tissue biopsy.We expect this RBC interface strategy will inspire further biomimetic interface construction for rare cell analysis.

Cytokeratin和CD133在肺腺癌患者外周血中的联合检测及临床病理分析

目的联合检测肺腺癌患者外周血中细胞角蛋白(cytokeratin,CK,肺腺癌循环肿瘤细胞阳性)和CD133基因(肺癌干细胞标志物)的表达,探讨二者在评估肺腺癌预后的临床价值。方法选取2014年6月至2016年6月昆明总医院心胸外科和宣威市第一人民医院心胸外科的178例未化疗的肺腺癌手术患者,中位年龄59岁,其中男性78例,女性100例。收集患者术前外周血标本10 m L,细胞块法和CK(免疫细胞化学法)用于检测CTC,PCR法用于检测CD133表达。免疫组化法检测肺腺癌组织中CK、Vimentin(Vim)、TTF-1、Ki-67、CD133的表达,并分析与外周血CK和CD133表达的关系。根据外周血CK和CD133的检测结果,将病例分为CK/CD133双阳性组和非双阳性组,统计学分析两组间临床病理因素的差异。结果 178例肺腺癌患者外周血CTC(CK阳性)的检出率为48.3%(86/178),与癌组织中Ki-67、Vim表达显著正相关(P<0.05);外周血的CD133阳性表达率为66.9%(119/178),与癌组织Vim、CD133表达显著正相关(P<0.05);外周血CK/CD133双阳组53例(29.8%),双阳组淋巴结转移率显著增高,肺腺癌组织学分化级别显著降低,临床分期显著提高,转移率显著增高(P<0.05)。结论肺腺癌患者外周血中CK与CD133双阳性表达提示外周血存在干性特征的循环肿瘤细胞,表明预后不良,联合检测CK与CD133可用于肺腺癌患者预后监测和指导治疗。

Midkine mRNA在食管鳞癌患者外周血中的表达及其临床意义

目的:探讨靶基因中期因子(MK)在食管鳞癌患者外周血中的表达及其与食管鳞癌生物学行为的关系。方法:采用巢式RT-PCR方法检测54例食管鳞癌患者外周血的MK mRNA。10例正常健康志愿者外周血为阴性对照,11例食管鳞癌肿瘤组织为阳性对照。结果:54例食管鳞癌患者外周血MK mRNA阳性率为61.11%(33/54),并与食管鳞癌患者淋巴结转移有显著相关性(P<0.05),而健康成人外周血则无一例出现阳性。结论:应用巢式RT-PCR方法检测食管癌患者外周血中的MKmRNA具有较高的敏感性和特异性,它有望成为判断食管鳞癌恶性程度、转移、复发和监测疗效的客观指标。

低剂量CT联合外周血循环肿瘤细胞在肺癌早期诊断中的价值研究

目的 探究低剂量CT联合外周血循环肿瘤细胞(CTC)在肺癌早期诊断中的价值。方法 选取2019年12月~2022年12月期间本院收治的75例早期肺癌患者,作为肺癌组,同期选取于本院进行治疗的59例肺部良性病变患者为对照组,收集两组患者的临床资料。所有患者均进行低剂量CT扫描,并检测CTC水平,Logistic回归分析明确影响肺癌发生的因素,根据受试者工作特征(ROC)曲线分析低剂量CT与CTC检测对肺癌早期诊断的预测价值。结果 肺癌组有分叶征、毛刺征及胸膜凹陷征人数均高于对照组(P<0.05);肺癌组有吸烟史、CTC阳性人数均高于对照(P<0.05);经Logistic回归分析,有吸烟史、毛刺征、胸膜凹陷征及CTC阳性是影响肺癌发生的独立危险因素(P<0.05);经RDC分析显示,分叶征诊断肺癌早期的AUC值为0.747,95%CI为0.664~0.818;胸膜凹陷征的AUC值为0.789,95%CI为0.710~0.854,CTC预测的AUC值为0.840,95%CI为0.767-0.898,三者联合预测的AUC值为0.878,95%CI为0.811~0.928。结论 低剂量CT表现中分叶征、胸膜凹陷征及CTC对于肺癌早期诊断均有一定的参考价值,三者联合用于肺癌的早期诊断具有更高的价值。

肿瘤外周血炎症标志物与^(18)F-FDG PET/CT代谢参数的相关性

外周血炎症标志物如中性粒细胞/淋巴细胞比值(NLR)、血小板/淋巴细胞比值(PLR)等能够在一定程度上反映肿瘤内部炎性细胞反应性增生,同时,^(18)F-FDG PET/CT代谢参数与肿瘤内部炎性细胞反应性增生之间也存在相关性,但是目前肿瘤代谢参数和外周血炎症标志物之间关系的报道较少,因此本文将从肿瘤外周血炎症标志物、肿瘤内部炎性细胞反应性增生、^(18)F-FDG PET/CT代谢参数等三方面之间的关系出发,对^(18)F-FDG PET/CT代谢参数和外周血炎症标志物之间的相关性作文献综述。

膀胱癌患者外周血CTC细胞中survivin的表达及意义

目的分析膀胱癌患者外周血循环肿瘤细胞(CTC)中生存蛋白(survivin)的表达及意义。方法选择空军军医大学唐都医院于2019年1月至2020年11月期间收治的54例膀胱癌患者为研究对象,采集其外周静脉血,采用CanPatrol技术检测CTC,免疫组化法检测survivin水平,比较不同肿瘤直径、病理分级、肿瘤分期(T分期)、肿瘤数目患者的外周血CTC、survivin的表达差异,以及不同类型CTC中survivin阳性率的差异。结果54例膀胱癌患者中25例检出CTC,阳性率为46.30%,主要包括13例上皮型CTC、7例间质型CTC、5例为混合型。上皮型CTC中,7例为survivin阳性表达,占53.85%;间质型CTC中,均为survivin阳性表达,占100.00%;混合型CTC中,4例survivin阳性表达,占80.00%。间质型survivin阳性率显著高于上皮型和混合型CTC,差异有统计学意义(P<0.05)。肿瘤直径<3 cm、分期<T2、单发肿瘤的CTC检验阳性率更高,差异有统计学意义(P<0.05);不同病理分级之间的CTC检测阳性率比较,差异无统计学意义(P>0.05)。肿瘤病理分级中高级别、分期≥T2的survivin检测阳性率分别为24.07%、25.93%,明显高于低级别、分期<T2的9.26%、7.41%,差异均有统计学意义(P<0.05);不同肿瘤直径、肿瘤数目的survivin检测阳性率之间比较差异均无统计学意义(P>0.05)。结论膀胱癌患者中,间质型CTC的survivin阳性表达率较其他型别明显更高,且其表达与膀胱癌患者病理分期、分级之间具有一定相关性。

3D腔镜甲状腺全切术治疗分化型甲状腺癌的效果及对外周血循环肿瘤细胞、肿瘤标志物的影响

目的探究3D腔镜甲状腺全切术(TET)在分化型甲状腺癌(DTC)患者治疗中的应用价值。方法选取2020年9月至2022年9月于新乡市中心医院头颈乳腺外科治疗的60例DTC患者为研究对象,采用随机数表法分为观察组和对照组,每组30例。观察组行3D TET治疗,对照组行常规2D腔镜TET治疗。比较两组患者的手术情况及术后恢复指标、并发症、手术前后循环肿瘤细胞(CTC)水平和肿瘤标志物[甲状腺球蛋白(TG)、降钙素(CTN)、半乳糖血凝素-3(GAL-3)、癌胚抗原(CEA)]水平。结果观察组患者的手术时间、术中及术后出血量均较对照组短(少),淋巴结清扫数量较对照组多,差异均有统计学意义(P<0.05);术后3 d,两组患者的CTC水平较术前升高,且观察组为(27.12±5.84)×10个/mL,明显低于对照组的(32.17±6.49)×10个/mL,差异有统计学意义(P<0.05);术前及术后1个月、3个月,两组患者的血清TG、CTN、GAL-3、CEA较术前持续下降,术后1个月,观察组患者的血清TG、CTN、GAL-3、CEA水平分别为(92.86±11.29)μg/L、(11.35±2.46)ng/L、(4.61±1.08)ng/mL、(19.87±3.05)μg/L,明显低于对照组的(99.32±12.78)μg/L、(12.61±2.37)ng/L、(5.33±1.53)ng/mL、(21.46±2.96)μg/L,差异均有统计学意义(P<0.05);观察组患者术后并发症总发生率为16.67%,略低于对照组的33.33%,但差异无统计学意义(P>0.05)。结论3D TET是DTC安全可靠的治疗方式,可优化手术操作,缩短手术时间,减少术中出血,提高淋巴结清扫范围,减缓CTC分泌。

痤疮患者外周血IL-17、TNF-α及Th22细胞水平与痤疮严重程度的相关性研究

目的探究痤疮患者外周血白介素-17(IL-17)、肿瘤坏死因子α(TNF-α)及外周血辅助性T细胞22(Th22)细胞水平与痤疮严重程度的相关性。方法选择2020年5月至2022年1月门诊进行治疗的痤疮患者78例作为观察组,同一阶段体检的健康体检者47例作为对照组,比较2组外周血IL-17、TNF-α、IL-22、Th22细胞水平。按Pillsbury法将78例痤疮患者分为轻度(Ⅰ级)组19例,中度(Ⅱ~Ⅲ级)组39例,重度(Ⅳ级)组20例,比较3组血清外周血IL-17、TNF-α、IL-22、Th22细胞水平。并进一步分析外周血IL-17、TNF-α及Th22细胞水平与痤疮严重程度的相关性。结果相较于对照组,观察组IL-17、TNF-α、IL-22及Th22细胞水平均明显上调(P<0.05)。相较于轻度组,中、重度组IL-17、TNF-α、IL-22、Th22细胞水平均明显上调(P<0.05);相较于中度组,重度组IL-17、TNF-α、IL-22、Th22细胞水平均明显上调(P<0.05)。IL-17、TNF-α、Th22预测痤疮严重程度的曲线下面积(AUC)分别为0.736、0.750、0.849,灵敏度分别为94.74%、95.53%、100.00%,特异度分别为51.28%、61.54%、71.79%。IL-17、TNF-α、Th22细胞水平与痤疮患者严重程度均呈正相关(r=0.544,0.443,0.691,P=0.032,0.040,0.021)。结论痤疮患者外周血中IL-17、TNF-α、Th22细胞水平均明显上调,与病情严重程度相关,随病情严重程度增加而上调,在预测痤疮严重程度方面具有重要价值。